Treatment of hemodialysis AV graft stenosis: Stents resurgent  by White, John J. et al.
Kidney International, Vol. 67 (2005), pp. 772–773
EDITORIAL
Treatment of hemodialysis AV graft stenosis: Stents resurgent
Complications of the hemodialysis synthetic arteriove-
nous graft (AVG) cause significant morbidity and mortal-
ity, and increase the cost of access-related care. Stenosis
at the venous anastomosis or outflow vein leads to stasis,
thrombosis, and ultimately, AVG abandonment. Conse-
quently, survival of AVGs is less than 50% at three years
[1]. The K/DOQI panel reasoned that delaying correction
of stenosis until after thrombosis results in tight stenoses
that are difficult to correct by percutaneous translumi-
nal angioplasty (PTA). It was hoped that AVG survival
would be improved by applying prospective surveillance
followed by early preemptive PTA of hemodynamically
significant stenosis. It is clear that surveillance can detect
subcritical stenoses, but three recent randomized con-
trolled trials have challenged the belief that surveillance
improves AVG survival [2–4].
These disappointing results indicate that preemptive
PTA may not have the beneficial effect that was origi-
nally hypothesized. This has led to renewed interest in
application of endovascular stents to grafts that are resis-
tant to PTA. Although previous studies have often been
disappointing [5], the study by Sreenarasimhaiah et al
[6] in this issue of Kidney International underscores the
possibility that stents may prolong AVG survival.
The many types of available stents and the nonuniform
study designs and documentation make it difficult to com-
pare previous studies. Stents are currently available in
stainless steel (Wallstent, Gianturco), nitinol [nickel and
titanium alloy (e.g., SMART, Symphony, and Memoth-
erm)], and as coated stents [nitinol coated with Dacron
(e.g., Cragg), and cobalt/titanium coated with PTFE (e.g.,
Wallgraft)]. Previous studies have employed Wallstent,
Gianturco, and Cragg stents with inconsistent success
in prolonging AVG survival. However, the nitinol self-
expanding SMART stent may be better suited for use in
AVGs because of important physical characteristics, such
as superior flexibility and ability to be placed at areas of
angulation [7].
Vogel et al [7] recently retrospectively studied the
use of SMART stents to treat PTA-resistant stenosis in
AVGs. Criteria for inclusion in the study included re-
current stenosis less than three months after PTA, ve-
nous rupture, and greater than 50% stenosis after PTA.
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Of 19 patients who had stents placed at sites of previ-
ous PTA, primary (unassisted) patency at six months in-
creased from 14% for PTA without stenting to 72% after
PTA with stenting; mean primary patency increased from
2.5 to 10.6 months.
Sreenarasimhaiah et al [6] obtained similar encourag-
ing results in this issue of Kidney International. They stud-
ied the clinical course of 34 patients after placement of
SMART stents as treatment of venous anastomotic le-
sions in thrombosed AVGs unresponsive to PTA. Criteria
for inclusion in the study included PTA of the same lesion
within the previous three months, lumen collapse imme-
diately post-PTA because of elastic recoil, or significant
residual stenosis post-PTA. Treatment with clopidogrel
post-procedure was an additional feature of the study.
The AVGs averaged of 17.9 months of age, and 84% had
one or more endovascular or surgical procedures before
this thrombosis. The results of this study are remarkable:
primary patency after stent placement was 63% and 36%
at six months and one year, respectively, and secondary
(assisted) patency was 88% and 86% at six months and
one year, respectively.
In attempting to explain this study’s encouraging re-
sults, a potential role of clopidogrel should be considered.
In AVGs, previous studies with bare-metal stents have
not employed currently available antiplatelet agents. It
should be noted that antiplatlet therapy has become the
standard of care after intracoronary stent implantation.
Regarding AVGs, Sreedhara et al demonstrated a signif-
icant reduction in the number of thromboses in newly
created AVGs that were treated with dipyridamole com-
pared with placebo, but there was no benefit in previously
thrombosed AVGs [8]. However, more recent experience
with antiplatelet agents has not been encouraging. A ran-
domized controlled trial evaluated the role of clopidogrel
plus aspirin in preventing AVG thrombosis [9]. The study
was discontinued early because of a marked increase
in bleeding episodes in the treatment group. The study
showed no difference in thrombosis rates between the
treatment and placebo groups. Thus, it is unclear whether
clopidogrel played a significant role in the favorable out-
come of Sreenarasimhaiah et al’s study [6]. K/DOQI does
not currently recommend use of antiplatelet agents or an-
ticoagulation to prevent AVG thrombosis.
The study by Sreenarasimhaiah et al indicates that de-
spite improved patency, neointimal hyperplasia contin-
ues unabated [6]. For example, in the 21 of 34 patients
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that required repeat procedures, 81% (17/21) had lesions
outside the stent. Moreover, in 43% of repeat procedures,
the original stented lesion was not implicated as the cause
of AVG dysfunction. Thus, stenting may delay abandon-
ment of the AVG, but does not provide the more de-
sirable (but not yet attainable) definitive prevention or
treatment of neointimal hyperplasia. Nevertheless, this
result, if confirmed, is noteworthy because any treatment
that prolongs access function delays the day when the
patient runs out of access sites.
In conclusion, we must find better ways to prevent and
treat neointimal hyperplasia. Novel strategies to prevent
AV graft stenosis by using pharmacologic and other ther-
apies are underway (NIH DAC Study and others). Nev-
ertheless, until truly effective therapies are found, our
options are limited. In light of this new data with nitinol
stents, we must push for randomized controlled trials that
will test their efficacy as an adjunct to PTA. If future stud-
ies demonstrate that stent placement prolongs access sur-
vival and reduces intervention, the added costs of stents
may be offset by decreased access morbidity and reduced
total access-related costs. Drug-eluting stents are very ex-
pensive but may be even more effective. PTA combined
with stent deployment may be the combination that opens
a new era of improved therapy of recurrent stenosis.
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